Elevance Health (XTER:A58) Research & Development: €0 Mil (TTM As of Mar. 2026)


XTER:A58 Elevance Health Inc XTER:A58
89 GF Score
Price €343.40
GF Value €441.91
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Elevance Health Research & Development?

Elevance Health XTER:A58 +1.21% 89 Research & Development is €0 Mil as of Mar. 2026. GuruFocus rates XTER:A58 with a GF Score™ of 89/100 and a GF Value™ of €441.91 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Elevance Health's Research & Development for the three months ended in Mar. 2026 was €0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0 Mil.

Elevance Health  (XTER:A58) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Elevance Health Research & Development Related Terms

Elevance Health Research & Development Historical Data

* Premium members only.

The historical data trend for Elevance Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elevance Health Research & Development Chart

Elevance Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Elevance Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XTER:A58
89GF Score
Elevance Health Inc XTER:A58
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elevance Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0 Mil mean?
Elevance Health (XTER:A58) has a Research & Development of €0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Elevance Health and its competitors.
Is Elevance Health's Research & Development too high?
Elevance Health's current Research & Development is €0 Mil. Overall, Elevance Health has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Elevance Health's Research & Development compare to CI and CVS?
Elevance Health's Research & Development of €0 Mil can be compared against companies in the Healthcare Plans industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Plans company?
A good Research & Development depends on the Healthcare Plans industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Elevance Health and its competitors. Elevance Health's current Research & Development is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elevance Health stock overvalued right now?
Based on GuruFocus' analysis, Elevance Health (XTER:A58) is currently considered Modestly Undervalued. The stock's GF Value™ is €441.91, compared to a current price of €343.40 — trading 22.3% below its estimated fair value. The current Research & Development is €0 Mil. Elevance Health's overall GF Score™ is 89/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Elevance Health (XTER:A58), the current Research & Development is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Elevance Health (XTER:A58) Overvalued in 2026?

Based on GuruFocus' analysis, Elevance Health stock appears to be undervalued. The current stock price of €343.40 is trading 22.3% below its estimated GF Value™ of €441.91. GuruFocus considers Elevance Health to be Modestly Undervalued.

Key valuation signals for XTER:A58:

  • Research & Development: €0 Mil
  • GF Value™: €441.91 vs. price of €343.40 (22.3% below fair value)
  • GF Score™: 89/100 with 7 warning signs

No single metric tells the full story. See the XTER:A58 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Elevance Health Business Description

Address 220 Virginia Avenue, Indianapolis, IN, USA, 46204
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states in government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.
89GF Score

Get the complete analysis for XTER:A58

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€343.40
Price
€441.91
GF Value